Several other equities research analysts have also commented on the stock. Stifel Nicolaus reaffirmed a hold rating and issued a $10.00 price target on shares of DBV TECHNOLOGIE/S in a report on Wednesday, March 6th. JMP Securities reaffirmed a buy rating and issued a $20.00 price target on shares of DBV TECHNOLOGIE/S in a report on Wednesday, March 6th. Finally, Zacks Investment Research lowered shares of DBV TECHNOLOGIE/S from a buy rating to a hold rating in a report on Friday, April 12th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and three have given a buy rating to the stock. The stock has a consensus rating of Hold and a consensus target price of $14.91.
NASDAQ:DBVT opened at $8.99 on Tuesday. DBV TECHNOLOGIE/S has a one year low of $3.60 and a one year high of $25.77. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.30 and a current ratio of 3.34.
About DBV TECHNOLOGIE/S
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults.
Further Reading: What is a Derivative?
Receive News & Ratings for DBV TECHNOLOGIE/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV TECHNOLOGIE/S and related companies with MarketBeat.com's FREE daily email newsletter.